Actively Recruiting
Randomized Double-Blind Trial of Oral Controlled-Ileocolonic-Release Nicotinamide for Mild to Moderately Active Ulcerative Colitis Treatment and Maintenance
Led by University Hospital Schleswig-Holstein · Updated on 2026-10-22
459
Participants Needed
25
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of two doses 2 gday and 3 gday of oral controlled-ileocolonic-release nicotinamide CICR-NAM compared to placebo in adults with mild to moderately active ulcerative colitis UC. This trial aims to improve intestinal inflammation by increasing nicotinamide supply in the ileocolonic region to positively influence the gut microbiota. The study is a double-blind, randomized, placebo-controlled phase IIIII trial. Participants are randomly assigned to one of three groups receiving either 2 gday CICR-NAM, 3 gday CICR-NAM, or placebo, taking six tablets daily to maintain blinding. The study includes a 12-week induction period followed by a 40-week maintenance period, resulting in 52 weeks of treatment. An optional open-label arm with 3 gday CICR-NAM is available for patients who complete induction but experience worsening disease. During the study, participants will take assigned tablets daily and attend visits for assessments. Researchers will monitor symptomatic remission at 12 weeks and clinical remission at 52 weeks. Evaluations include disease activity scores, endoscopy, and laboratory tests. Safety and treatment effects will be continuously monitored throughout the year-long trial. Participants adherence and response to treatment will be carefully tracked.
CONDITIONS
Brief Title
Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
Research Team
S
Stefan Schreiber, Prof. Dr. Dr. hc.
F
Friso Muijsers
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here